JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Floch, A.
Right arrow Articles by Cavero, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Floch, A.
Right arrow Articles by Cavero, I.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*OXYGEN

The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes

A Floch, L Tahraoui, P Sedivy and I Cavero

Rhone-Poulenc Rober, Centre de Recherche de Vitry-Alfortville, Vitry- sur-Seine, France.

In elicited (mineral oil) peritoneal guinea pig macrophages, there was a specific [3H]platelet activating factor (PAF) binding which displayed concentration dependency, saturability, high affinity (Kd = 2.2 +/- 0.2 nM, n = 15), elevated capacity (Bmax = 122,808 +/- 10,234 sites/cell, n = 15) and irreversibility. PAF(C16) and the PAF antagonists RP 59227, Ro 19-3704 and WEB 2086 prevented the binding of [3H]PAF. RP 59227 (Ki = 3.1 +/- 0.3 nM, n = 5) was about 5- and 8-fold more potent than Ro 19- 3704 and WEB 2086, respectively. In competition studies, RP 59227 produced dextral and concentration-dependent shifts of the sigmoidal inhibition curve of [3H]PAF binding by PAF(C16). Macrophages exposed to PAF produced chemiluminescence signals, the magnitude of which was concentration related (pD2 = 8.40 +/- 0.03, n = 13) and which were inhibited by the oxygen radical scavengers, superoxide dismutase, catalase, deferoxamine and mannitol. RP 59227 and WEB 2086 antagonized in a noncompetitive manner (pD'2 = 7.72 +/- 0.01 and 8.15 +/- 0.05, respectively) the control PAF concentration-response curve. By contrast, Ro 19-3704 behaved as a competitive antagonist (pA2 = 8.13 +/- 0.11). The apparent noncompetitive effects of RP 59227 were not due to undisplaceable binding to PAF receptors because washing of macrophages exposed to RP 59227 allowed the recovery of PAF luminescence and PAF binding. This procedure was poorly effective to lessen the inhibitory activity of WEB 2086. In human polymorphonuclear leukocytes, the weak potency of PAF was enhanced by 10-fold (pD2 = 7.61 +/- 0.06, n = 6) when polymorphonuclear leukocytes were primed for 10 min with fMLP (5 nM).(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 258, Issue 2, pp. 567-575, 08/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1991 by the American Society for Pharmacology and Experimental Therapeutics.